Search in:

Artificial Cells, Nanomedicine, and Biotechnology

An International Journal

Volume 47, 2019 - Issue 1

Submit an article Journal homepage

Open access

3,417

Views

CrossRef citations to date

Altmetric

Article

SHP2 inhibitor specifically suppresses the stemness of KRAS-mutant non-small cell lung cancer cells

Lei Jianga Department of Pharmacy, Anhui No.2 Provincial People’s Hospital, Hefei, China

Weiping Xub Research Department, The First Affiliated Hospital of USTC, Hefei, ChinaCorrespondence[email protected]

Yi Chena Department of Pharmacy, Anhui No.2 Provincial People’s Hospital, Hefei, China

Yue Zhanga Department of Pharmacy, Anhui No.2 Provincial People’s Hospital, Hefei, China

Pages 3231-3238 | Received 03 Jun 2019, Accepted 16 Jul 2019, Published online: 02 Aug 2019

Cite this article
https://doi.org/10.1080/21691401.2019.1646748
CrossMark

Full Article
Figures & data
References
Citations
Metrics
Licensing
Reprints & Permissions
View PDF PDF View EPUB EPUB

Citations (14)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Articles from other publishers (14)

Alireza Tojjari, Anwaar Saeed, Arezoo Sadeghipour, Razelle Kurzrock & Ludimila Cavalcante. (2023) Overcoming Immune Checkpoint Therapy Resistance with SHP2 Inhibition in Cancer and Immune Cells: A Review of the Literature and Novel Combinatorial Approaches. Cancers 15:22, pages 5384.
Crossref

Matthias Peindl, Claudia Göttlich, Samantha Crouch, Niklas Hoff, Tamara Lüttgens, Franziska Schmitt, Jesús Guillermo Nieves Pereira, Celina May, Anna Schliermann, Corinna Kronenthaler, Danjouma Cheufou, Simone Reu-Hofer, Andreas Rosenwald, Elena Weigl, Thorsten Walles, Julia Schüler, Thomas Dandekar, Sarah Nietzer & Gudrun Dandekar. (2022) EMT, Stemness, and Drug Resistance in Biological Context: A 3D Tumor Tissue/In Silico Platform for Analysis of Combinatorial Treatment in NSCLC with Aggressive KRAS-Biomarker Signatures. Cancers 14:9, pages 2176.
Crossref

Yihui Song, Min Zhao, Huiqing Zhang & Bin Yu. (2022) Double-edged roles of protein tyrosine phosphatase SHP2 in cancer and its inhibitors in clinical trials. Pharmacology & Therapeutics 230, pages 107966.
Crossref

Chun‐Jung Chang, Chiou‐Feng Lin, Bing‐Chang Chen, Pei‐Yun Lin & Chia‐Ling Chen. (2021) SHP2 : The protein tyrosine phosphatase involved in chronic pulmonary inflammation and fibrosis . IUBMB Life 74:2, pages 131-142.
Crossref

Elena Corral de la Fuente, Maria Eugenia Olmedo Garcia, Ana Gomez Rueda, Yolanda Lage & Pilar Garrido. (2022) Targeting KRAS in Non-Small Cell Lung Cancer. Frontiers in Oncology 11.
Crossref

M. Reck, D.P. Carbone, M. Garassino & F. Barlesi. (2021) Targeting KRAS in non-small-cell lung cancer: recent progress and new approaches. Annals of Oncology 32:9, pages 1101-1110.
Crossref

Yiwei Zhang, Zhipeng Qi, Wenjie Wang, Lei Wang, Fuliang Cao, Linguo Zhao & Xianying Fang. (2021) Isovitexin Inhibits Ginkgolic Acids-Induced Inflammation Through Downregulating SHP2 Activation. Frontiers in Pharmacology 12.
Crossref

Leiming Xia, Fan Yang, Xiao Wu, Suzhi Li, Chen Kan, Hong Zheng & Siying Wang. (2021) SHP2 inhibition enhances the anticancer effect of Osimertinib in EGFR T790M mutant lung adenocarcinoma by blocking CXCL8 loop mediated stemness. Cancer Cell International 21:1.
Crossref

Qing Nian, Jinhao Zeng, Li He, Yu Chen, Zhiqiang Zhang, Fernando Rodrigues-Lima, Liyun Zhao, Xuanlin Feng & Jianyou Shi. (2021) A small molecule inhibitor targeting SHP2 mutations for the lung carcinoma. Chinese Chemical Letters 32:5, pages 1645-1652.
Crossref

Mengzhu Zheng, Yang Liu, Canrong Wu, Kaiyin Yang, Qiqi Wang, Yirong Zhou, Lixia Chen & Hua Li. (2021) Novel PROTACs for degradation of SHP2 protein. Bioorganic Chemistry 110, pages 104788.
Crossref

Lei Dong, Da Han, Xinyi Meng, Mengchuan Xu, Chuwen Zheng & Qin Xia. (2021) Activating Mutation of SHP2 Establishes a Tumorigenic Phonotype Through Cell-Autonomous and Non-Cell-Autonomous Mechanisms. Frontiers in Cell and Developmental Biology 9.
Crossref

Rati Kailash Prasad Tripathi & Senthil Raja Ayyannan. (2020) Emerging chemical scaffolds with potential SHP2 phosphatase inhibitory capabilities – A comprehensive review. Chemical Biology & Drug Design 97:3, pages 721-773.
Crossref

Zhendong Song, Meijing Wang, Yang Ge, Xue-Ping Chen, Ziyang Xu, Yang Sun & Xiao-Feng Xiong. (2021) Tyrosine phosphatase SHP2 inhibitors in tumor-targeted therapies. Acta Pharmaceutica Sinica B 11:1, pages 13-29.
Crossref

J. Matthew Rhett, Imran Khan & John P. O’Bryan. 2020. 69 146 .

Share icon
Back to Top

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references

SHP2 inhibitor specifically suppresses the stemness of KRAS-mutant non-small cell lung cancer cells

Articles from other publishers (14)

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

SHP2 inhibitor specifically suppresses the stemness of KRAS-mutant non-small cell lung cancer cells

Citations (14)

Articles from other publishers (14)

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date